1. Home
  2. CERT vs MGTX Comparison

CERT vs MGTX Comparison

Compare CERT & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CERT

Certara Inc.

HOLD

Current Price

$5.49

Market Cap

808.9M

Sector

Technology

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$11.74

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
MGTX
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
808.9M
909.1M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
CERT
MGTX
Price
$5.49
$11.74
Analyst Decision
Buy
Strong Buy
Analyst Count
10
7
Target Price
$11.67
$24.57
AVG Volume (30 Days)
4.1M
778.4K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
33.02
EPS
N/A
N/A
Revenue
$418,838,000.00
$81,391,000.00
Revenue This Year
$4.18
$141.38
Revenue Next Year
$5.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.75
144.57
52 Week Low
$4.45
$6.31
52 Week High
$13.88
$12.28

Technical Indicators

Market Signals
Indicator
CERT
MGTX
Relative Strength Index (RSI) 49.61 70.94
Support Level $5.08 $7.10
Resistance Level $6.37 $11.85
Average True Range (ATR) 0.36 0.61
MACD 0.02 0.26
Stochastic Oscillator 39.45 83.78

Price Performance

Historical Comparison
CERT
MGTX

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: